Clinical-stage biopharmaceutical company developing oral small molecule therapies for cancer and inflammatory diseases.
RAPT Therapeutics, Inc., a pioneering clinical-stage biopharmaceutical firm rooted in immunology, is dedicated to advancing the discovery, development, and commercialization of oral small molecule therapies. Focused on addressing critical unmet needs in oncology and inflammatory diseases, RAPT Therapeutics leverages its innovative pipeline to bring transformative treatments to patients worldwide.
At the forefront of its portfolio is RPT193, a potent C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues, offering promising avenues for treating inflammatory conditions. Additionally, the company's lead oncology candidate, FLX475, an oral CCR4 antagonist, is undergoing Phase 1/2 clinical trials. These trials aim to evaluate. FLX475 as both a monotherapy and in combination with pembrolizumab for patients with advanced cancer.
RAPT Therapeutics also focuses on developing a hematopoietic progenitor kinase 1 (HPK1) inhibitor, highlighting its commitment to expanding therapeutic options in oncology. Formerly known as FLX Bio, Inc., the company rebranded as RAPT Therapeutics, Inc. in 2019 to reflect its evolving focus and expanded pipeline.
Headquartered in South San Francisco, California, RAPT Therapeutics, Inc. was established in 2015. The company's strategic location in the heart of the biotechnology hub allows it to harness cutting-edge research and innovation, driving forward its mission to deliver impactful therapies that improve patient outcomes and quality of life.